X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (12714) 12714
Newspaper Article (180) 180
Newsletter (82) 82
Book Chapter (54) 54
Magazine Article (8) 8
Dissertation (7) 7
Book / eBook (2) 2
Conference Proceeding (2) 2
Government Document (2) 2
Publication (2) 2
Trade Publication Article (2) 2
Streaming Video (1) 1
Web Resource (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (7264) 7264
male (4875) 4875
animals (4732) 4732
female (3662) 3662
adenosine (3575) 3575
middle aged (2373) 2373
aged (1826) 1826
cardiac & cardiovascular systems (1789) 1789
rats (1736) 1736
adult (1577) 1577
adenosine triphosphate - metabolism (1486) 1486
pharmacology & pharmacy (1348) 1348
mice (1327) 1327
adenosine triphosphatase (1286) 1286
proteins (1153) 1153
analysis (1124) 1124
treatment outcome (1043) 1043
adenosine triphosphate (1000) 1000
metabolism (994) 994
oxidative stress (991) 991
time factors (983) 983
research (965) 965
apoptosis (876) 876
adenosine - analogs & derivatives (857) 857
adenosine - adverse effects (827) 827
cell biology (819) 819
biochemistry & molecular biology (804) 804
medicine (802) 802
dose-response relationship, drug (801) 801
physiological aspects (797) 797
clopidogrel (796) 796
neurosciences (788) 788
inhibition (778) 778
research article (766) 766
care and treatment (763) 763
risk factors (762) 762
cardiology (758) 758
kinases (751) 751
health aspects (748) 748
ischemia (729) 729
rodents (726) 726
physiology (724) 724
inflammation (711) 711
gene expression (700) 700
ticlopidine - analogs & derivatives (697) 697
medicine & public health (689) 689
activation (680) 680
enzymes (670) 670
hematology (663) 663
adenosine diphosphate (653) 653
cancer (653) 653
patients (648) 648
studies (648) 648
adenosine - administration & dosage (646) 646
expression (643) 643
surgery (642) 642
disease models, animal (632) 632
platelet aggregation - drug effects (629) 629
adenosine - therapeutic use (624) 624
atp (610) 610
multidisciplinary sciences (606) 606
abridged index medicus (604) 604
heart (600) 600
cardiovascular disease (591) 591
oncology (587) 587
platelet aggregation inhibitors - therapeutic use (580) 580
drug therapy (569) 569
rats, sprague-dawley (561) 561
mitochondria (560) 560
science (558) 558
percutaneous coronary intervention (540) 540
adenosine - pharmacology (539) 539
phosphorylation (528) 528
aspirin (525) 525
toxicology (525) 525
prospective studies (519) 519
heart attacks (517) 517
peripheral vascular disease (516) 516
mortality (502) 502
toxicity (496) 496
cells (494) 494
cardiovascular (492) 492
signal transduction (490) 490
pharmacology (486) 486
electrocardiography (485) 485
medicine, research & experimental (481) 481
biology (478) 478
diabetes (474) 474
immunology (474) 474
therapy (474) 474
disease (473) 473
clinical trials (472) 472
review (461) 461
acute coronary syndromes (453) 453
medical research (453) 453
rats, wistar (451) 451
coronary heart disease (448) 448
platelet aggregation inhibitors - adverse effects (447) 447
cardiac patients (445) 445
ticagrelor (440) 440
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (12740) 12740
German (105) 105
Japanese (89) 89
Russian (83) 83
Spanish (42) 42
French (33) 33
Italian (26) 26
Chinese (17) 17
Polish (12) 12
Portuguese (9) 9
Dutch (5) 5
Korean (4) 4
Norwegian (4) 4
Danish (3) 3
Slovak (3) 3
Romanian (2) 2
Turkish (2) 2
Ukrainian (2) 2
Bulgarian (1) 1
Czech (1) 1
Serbian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


JACC (Journal of the American College of Cardiology), ISSN 0735-1097, 2011, Volume 58, Issue 22, pp. 2263 - 2269
Chronic kidney disease (CKD) is prevalent and affects an ever-increasing proportion of patients presenting with acute coronary syndrome (ACS). Patients with... 
Cardiovascular | Internal Medicine | non–ST-segment elevation myocardial infarction | chronic kidney disease | bleeding | ST-segment elevation myocardial infarction | unstable angina | acute coronary syndrome(s) | antiplatelet | antithrombotic | nonST-segment elevation myocardial infarction | CARDIAC & CARDIOVASCULAR SYSTEMS | WAVE MYOCARDIAL-INFARCTION | HIGH-RISK PATIENTS | GLYCOPROTEIN IIB/IIIA INHIBITORS | non-ST-segment elevation myocardial infarction | MOLECULAR-WEIGHT HEPARIN | PLATELET INHIBITION | DOUBLE-BLIND | ST-SEGMENT ELEVATION | STAGE RENAL-DISEASE | UNFRACTIONATED HEPARIN | ARTERY-DISEASE | Piperazines - administration & dosage | Prasugrel Hydrochloride | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Heparin - administration & dosage | Thiophenes - administration & dosage | Recombinant Proteins - adverse effects | Heparin - adverse effects | Hirudins - administration & dosage | Aspirin - administration & dosage | Dose-Response Relationship, Drug | Fibrinolytic Agents - adverse effects | Acute Coronary Syndrome - complications | Aspirin - adverse effects | Adenosine - adverse effects | Platelet Aggregation Inhibitors - administration & dosage | Ticlopidine - adverse effects | Ticlopidine - administration & dosage | Polysaccharides - administration & dosage | Kidney Diseases - complications | Platelet Aggregation Inhibitors - adverse effects | Peptide Fragments - administration & dosage | Polysaccharides - adverse effects | Clinical Trials as Topic | Uremia - complications | Adenosine - administration & dosage | Piperazines - adverse effects | Recombinant Proteins - administration & dosage | Ticlopidine - analogs & derivatives | Platelet Glycoprotein GPIIb-IIIa Complex - antagonists & inhibitors | Acute Coronary Syndrome - drug therapy | Adenosine - analogs & derivatives | Hirudins - adverse effects | Fibrinolytic Agents - administration & dosage | Peptide Fragments - adverse effects | Hemorrhage - chemically induced | Chronic Disease | Care and treatment | Chronic kidney failure | Cardiac patients | Cardiology | Coronary heart disease | Health aspects | Cardiovascular agents | Medical colleges | Mortality | Heart attacks | Drug therapy | Acute coronary syndromes | Coronary vessels
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 377, Issue 16, pp. 1513 - 1524
In this trial, dabigatran plus a P2Y 12 inhibitor was compared with warfarin plus a P2Y 12 inhibitor and aspirin after PCI in patients with atrial... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | HEART-DISEASE | MYOCARDIAL-INFARCTION | ORAL ANTICOAGULATION | 2011 ACCF/AHA/SCAI GUIDELINE | AMERICAN-COLLEGE | ASSOCIATION TASK-FORCE | TRIPLE THERAPY | ANTIPLATELET THERAPY | CONSENSUS DOCUMENT | Dabigatran - adverse effects | Ticlopidine - therapeutic use | Humans | Middle Aged | Warfarin - adverse effects | Male | Risk | Dabigatran - therapeutic use | Incidence | Warfarin - therapeutic use | Purinergic P2Y Receptor Antagonists - adverse effects | Drug Therapy, Combination - adverse effects | Adenosine - adverse effects | Adenosine - therapeutic use | Female | Aspirin - therapeutic use | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Purinergic P2Y Receptor Antagonists - therapeutic use | Hemorrhage - epidemiology | Atrial Fibrillation - drug therapy | Atrial Fibrillation - therapy | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Clopidogrel | Aged | Hemorrhage - chemically induced | Percutaneous Coronary Intervention | Warfarin | Atrial fibrillation | Dosage and administration | Research | Thromboembolism | Hemorrhage | Health aspects | Myocardial infarction | Cerebral infarction | Cardiac arrhythmia | Anticoagulants | Aspirin | Stroke | Embolisms | Preventive medicine | Thrombosis | Bleeding | Embolism | Fibrillation | Cardiology | Drug therapy | Drug dosages | Geriatrics
Journal Article
The Journal of surgical research, ISSN 0022-4804, 10/2019, Volume 242, pp. 157 - 165
Limited data exist that compare the predominant cardiac preservation solutions (CPSs). The United Network for Organ Sharing database was retrospectively... 
Procurement | Heart transplant | Preservation solution | SURGERY | HYPOTHERMIC STORAGE | ISCHEMIA | COLD-STORAGE | CELSIOR SOLUTION | TRIAL | RECOVERY | ARREST | UW SOLUTION | UNIVERSITY-OF-WISCONSIN | CARDIOPLEGIC SOLUTION | Heart Failure - surgery | Electrolytes - adverse effects | Follow-Up Studies | Glutamates - adverse effects | Organ Preservation - adverse effects | Humans | Middle Aged | Organ Preservation - methods | Male | Histidine - adverse effects | Young Adult | Graft Rejection - epidemiology | Cardioplegic Solutions - adverse effects | Adenosine - adverse effects | Potassium Chloride - adverse effects | Adult | Female | Retrospective Studies | Disaccharides - adverse effects | Heart Failure - mortality | Glucose - adverse effects | Mannitol - adverse effects | Organ Preservation Solutions - adverse effects | Procaine - adverse effects | Graft Rejection - prevention & control | Heart Transplantation - adverse effects | Graft Rejection - etiology | Treatment Outcome | Allografts - drug effects | Raffinose - adverse effects | Adolescent | Allopurinol - adverse effects | Survival Analysis | Heart - drug effects | Saline Solution - adverse effects | Aged | Glutathione - adverse effects | Graft Survival - drug effects | Insulin - adverse effects | Heart | Organ transplant recipients | Transplantation | Health aspects | Mortality
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2013, Volume 368, Issue 14, pp. 1303 - 1313
This clinical trial compared two antiplatelet regimens during PCI: oral clopidogrel and intravenous cangrelor. As compared with clopidogrel, cangrelor resulted... 
MEDICINE, GENERAL & INTERNAL | PERCUTANEOUS CORONARY INTERVENTION | METAANALYSIS | TICAGRELOR | CARDIOVASCULAR EVENTS | ACHIEVE OPTIMAL MANAGEMENT | CLOPIDOGREL PRETREATMENT | PRASUGREL | STANDARD THERAPY | ANTIPLATELET THERAPY | STRATEGIES | Double-Blind Method | Ticlopidine - therapeutic use | Humans | Middle Aged | Kaplan-Meier Estimate | Male | Adenosine Monophosphate - therapeutic use | Ticlopidine - analogs & derivatives | Adenosine Monophosphate - adverse effects | Angioplasty, Balloon, Coronary - adverse effects | Adenosine Monophosphate - analogs & derivatives | Hemorrhage - etiology | Intention to Treat Analysis | Myocardial Ischemia - therapy | Ticlopidine - adverse effects | Female | Aged | Myocardial Ischemia - mortality | Thrombosis - prevention & control | Platelet Aggregation Inhibitors - therapeutic use | Stents - adverse effects | Thrombosis - mortality | Platelet Aggregation Inhibitors - adverse effects | Drugs | Dose-response relationship (Biochemistry) | Usage | Cangrelor | Angioplasty | Patient outcomes | Product/Service Evaluations | Hemorrhage | Risk factors | Control | Ischemia | Dosage and administration | Drug therapy | Myocardial infarction | Adenosine | Heart attacks | Intravenous administration | Thrombosis | Patients | Bleeding | Dyspnea | Implants | Clopidogrel | Acute coronary syndromes | Respiration
Journal Article
Atherosclerosis, ISSN 0021-9150, 2014, Volume 233, Issue 2, pp. 568 - 578
...%) on intravenous P2Y12 inhibitors compared with clopidogrel. The primary efficacy endpoint was major adverse cardiac events (MACEs... 
Cardiovascular | Antiplatelet therapy | P2Y12 inhibitors | Coronary artery disease | Meta-analysis | CARDIAC & CARDIOVASCULAR SYSTEMS | HIGH-DOSE CLOPIDOGREL | RECEPTOR ANTAGONIST | IMPAIRED BIOAVAILABILITY | PLATELET INHIBITION | DOUBLE-BLIND | ASSOCIATION TASK-FORCE | PERIPHERAL VASCULAR DISEASE | PRASUGREL | INTERVENTION | ELEVATION MYOCARDIAL-INFARCTION | Prasugrel Hydrochloride | Thiophenes - therapeutic use | Myocardial Infarction - epidemiology | Humans | Quinazolinones - administration & dosage | Fibrinolytic Agents - adverse effects | Myocardial Infarction - therapy | Purinergic P2Y Receptor Antagonists - adverse effects | Adenosine - adverse effects | Ticlopidine - adverse effects | Ticagrelor | Myocardial Infarction - etiology | Multicenter Studies as Topic - statistics & numerical data | Administration, Oral | Piperazines - therapeutic use | Adenosine - administration & dosage | Piperazines - adverse effects | Ticlopidine - analogs & derivatives | Adenosine - analogs & derivatives | Acute Coronary Syndrome - etiology | Myocardial Infarction - prevention & control | Hemorrhage - chemically induced | Sulfonamides - administration & dosage | Piperazines - administration & dosage | Injections, Intravenous | Purinergic P2Y Receptor Antagonists - administration & dosage | Thiophenes - adverse effects | Ticlopidine - therapeutic use | Hemorrhage - prevention & control | Thiophenes - administration & dosage | Adenosine - therapeutic use | Stroke - epidemiology | Stents | Purinergic P2Y Receptor Antagonists - therapeutic use | Randomized Controlled Trials as Topic - statistics & numerical data | Stroke - prevention & control | Acute Coronary Syndrome - epidemiology | Coronary Restenosis - prevention & control | Coronary Artery Disease - drug therapy | Adenosine Monophosphate - therapeutic use | Adenosine Monophosphate - adverse effects | Sulfonamides - therapeutic use | Adenosine Monophosphate - administration & dosage | Adenosine Monophosphate - analogs & derivatives | Coronary Artery Disease - complications | Sulfonamides - adverse effects | Clopidogrel | Quinazolinones - therapeutic use | Thrombolytic Therapy - adverse effects | Quinazolinones - adverse effects | Acute Coronary Syndrome - prevention & control | Care and treatment | Coronary heart disease | Cardiac patients | Analysis
Journal Article
JAMA : the journal of the American Medical Association, ISSN 0098-7484, 04/2018, Volume 319, Issue 16, pp. 1677 - 1686
Journal Article
Journal of bone and mineral research, ISSN 0884-0431, 2012, Volume 27, Issue 2, pp. 309 - 318
Journal Article
JACC. Cardiovascular interventions, ISSN 1936-8798, 08/2017, Volume 10, Issue 16, pp. 1646 - 1658
Objectives This study compared adenosine-associated pleiotropic effects of the 2 P2Y receptor antagonists on vascular function, systemic inflammation, and circulating endothelial progenitor cells (EPCs... 
pleiotropic effect | prasugrel | diabetic patients | ticagrelor | acute coronary syndrome | ADENOSINE-FREE ASSESSMENT | CARDIAC & CARDIOVASCULAR SYSTEMS | HORMONE-THERAPY | COMBINED INTRACORONARY PRESSURE | ANTIPLATELET THERAPY | DIAGNOSTIC-ACCURACY | ACUTE MYOCARDIAL-INFARCTION | CARDIOVASCULAR-DISEASE | FLOW VELOCITY INFORMATION | POSTMENOPAUSAL WOMEN | LESION SEVERITY | Prospective Studies | Non-ST Elevated Myocardial Infarction - physiopathology | Percutaneous Coronary Intervention - mortality | Humans | Middle Aged | Acute Coronary Syndrome - mortality | Acute Coronary Syndrome - physiopathology | Male | Purinergic P2Y Receptor Antagonists - adverse effects | Percutaneous Coronary Intervention - instrumentation | Anti-Inflammatory Agents - adverse effects | Time Factors | Seoul | Adenosine - adverse effects | Adenosine - therapeutic use | Anti-Inflammatory Agents - therapeutic use | Non-ST Elevated Myocardial Infarction - therapy | Adult | Brachial Artery - physiopathology | Female | Brachial Artery - drug effects | Platelet Aggregation Inhibitors - therapeutic use | Ticagrelor | Stents | Purinergic P2Y Receptor Antagonists - therapeutic use | Endothelial Progenitor Cells - metabolism | Platelet Aggregation Inhibitors - adverse effects | Non-ST Elevated Myocardial Infarction - blood | Endothelial Progenitor Cells - drug effects | Inflammation Mediators - blood | Treatment Outcome | Prasugrel Hydrochloride - adverse effects | Biomarkers - blood | Acute Coronary Syndrome - blood | Prasugrel Hydrochloride - therapeutic use | Cross-Over Studies | Diabetes Mellitus, Type 2 - blood | Adenosine - analogs & derivatives | Diabetes Mellitus, Type 2 - mortality | Acute Coronary Syndrome - therapy | Aged | Vasodilation - drug effects | Non-ST Elevated Myocardial Infarction - mortality | Percutaneous Coronary Intervention - adverse effects
Journal Article
Journal Article